Clinical trials: Cognitive Fatigue
Multiple Sclerosis
Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)
The purpose of the study was the evaluation of the effect of a treatment for highly-active relapsing multiple sclerosis (RMS). This was the extension study to CLARIFY MS (NCT03369665), to assess cognitive impairment and health…
- Trial name
- NCT04776213
- Testing
- Mavenclad®
- Where
- 60 sites in Austria, Czechia and 8 more
- Volunteers
- 280 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany